Patents by Inventor Carl H. June

Carl H. June has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA engineered T cells for the treatment of cancer
    Patent number: 10421960
    Abstract: The present invention relates to compositions and methods for generating RNA Chimeric Antigen Receptor (CAR) transfected T cells. The RNA-engineered T cells can be used in adoptive therapy to treat cancer.
    Type: Grant
    Filed: September 17, 2012
    Date of Patent: September 24, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Yangbing Zhao
  • Treatment of cancer using anti-CD19 Chimeric Antigen Receptor
    Patent number: 10357514
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: July 23, 2019
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Carl H. June, David L. Porter, Marcela Maus, Mariusz Wasik, Saar Gill, Joseph Fraietta, Marco Ruella, John Byrd, Jason Dubovsky, Amy Johnson, Natarajan Muthusamy, Saad Kenderian, Joan Mannick, David Glass, Leon Murphy, Jennifer Brogdon, William Raj Sellers
  • Compositions and methods for targeting stromal cells for the treatment of cancer
    Patent number: 10329355
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention relates to targeting the stromal cell population in a tumor microenvironment. For example, in one embodiment, the invention provides a composition that is targeted to fibroblast activation protein (FAP). The invention includes a chimeric antigen receptor (CAR) which comprises an anti-FAP domain, a transmembrane domain, and a CD3zeta signaling domain.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: June 25, 2019
    Assignees: The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology
    Inventors: Carl H. June, Ellen Pure, Liang-Chuan Wang, Steven Albelda, John Scholler
  • Activation and Expansion of T-Cells Using an Engineered Multivalent Signaling Platform as a Research Tool
    Publication number: 20190177692
    Abstract: Provided are a system and methods for selectively inducing expansion of a population of T cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of CTLs, preferably human CTLs. In addition, T cell proliferation can be induced without the need for antigen, thus providing an expanded T cell population that is polyclonal with respect to antigen reactivity. Further provided are methods for using the system and methods to screen and identify antigens related to specific diseases or conditions, tumors, autoimmune disorders, or an infectious disease or pathogen, and to identify target molecule for research purposes, or for developing a vaccine based thereon.
    Type: Application
    Filed: July 26, 2018
    Publication date: June 13, 2019
    Inventors: Carl H. June, James L. Riley, Marcela Maus, Anna Kaskel, Robert Vonderheide
  • Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
    Patent number: 10308717
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: June 4, 2019
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania, University of Pittsburgh—of The Commonwealth System of Higher Education
    Inventors: Jennifer Brogdon, Laura Alexandra Johnson, Carl H. June, Andreas Loew, Marcela Maus, John Scholler, Hideho Okada
  • COMBINATION THERAPIES OF CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS
    Publication number: 20190151365
    Abstract: Provided are compositions and methods for treating diseases, e.g., cancers, e.g., diseases associated with expression of an antigen, e.g., CD 19, comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to the antigen, e.g., CD19, in combination with a PD-1 inhibitor.
    Type: Application
    Filed: July 28, 2017
    Publication date: May 23, 2019
    Applicants: Novartis AG, The Trustees of the University of Pennsylvania, The Trustees of the University of Pennsylvania
    Inventors: Oezlem Anak, Sanela Bilic, Jennifer Brogdon, John Scott Cameron, William Chou, Stephan Grupp, Danny Roland Howard, Jr., Randi Isaacs, Carl H. June, Simon Lacey, Shannon Maude, Jan J. Melenhorst, Stephen Shuster, Alfonso Quintas-Cardama
  • TREATMENT OF CANCER USING 5 HUMANIZED ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20190153061
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Application
    Filed: November 21, 2018
    Publication date: May 23, 2019
    Inventors: Jennifer Brogdon, Eugene Choi, Hilmar Erhard Ebersbach, David Jonathan Glass, Heather Huet, Carl H. June, Joan Mannick, Michael C. Milone, Leon Murphy, Gabriela Plesa, Celeste Richardson, Marco Ruella, Reshma Singh, Yongqiang Wang, Qilong Wu
  • Artificial antigen presenting cells and uses thereof
    Patent number: 10286066
    Abstract: The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf’ APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: May 14, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James L. Riley, Carl H. June, Robert H. Vonderheide, Nicole Aqui, Megan M. Davis
  • TREATMENT OF CANCER USING HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20190135940
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.
    Type: Application
    Filed: November 15, 2018
    Publication date: May 9, 2019
    Inventors: Jennifer Brogdon, Carl H. June, Andreas Loew, Marcela Maus, John Scholler
  • USE OF TRANS-SIGNALING APPROACH IN CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20190125797
    Abstract: The present invention provides compositions and methods for inducing a CAR mediated trans-signal in a T cell. The trans-signaling CAR T cells comprise a first CAR having a first signaling module and a second CAR having a distinct second signaling module. The present invention also provides cells comprising a plurality of types of CARs, wherein the plurality of types of CARs participate in trans-signaling to induce T cell activation.
    Type: Application
    Filed: October 1, 2018
    Publication date: May 2, 2019
    Inventors: Daniel J. Powell, JR., Carl H. June
  • Methods of making chimeric antigen receptor-expressing cells
    Patent number: 10273300
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 30, 2019
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Zoe Zheng
  • CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
    Patent number: 10253086
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: April 9, 2019
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Hans Bitter, Jennifer Mary Bordeaux, Barbara Brannetti, Jennifer Brogdon, Naveen Kumar Dakappagari, Saar Gill, Steven Highfill, Lu Huang, Carl H. June, Ju Young Kim, Ming Lei, Na Li, Andreas Loew, Elena Orlando, Marco Ruella, Thai Tran, Jimin Zhang, Li Zhou
  • Compositions and Methods for Generating a Persisting Population of T Cells Useful for the Treatment of Cancer
    Publication number: 20190085063
    Abstract: The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.
    Type: Application
    Filed: June 21, 2018
    Publication date: March 21, 2019
    Inventors: Matthew J. Frigault, Yangbing Zhao, John Scholler, Carl H. June
  • Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
    Patent number: 10221245
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: March 5, 2019
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Carl H. June, Andreas Loew, Marcela Maus, John Scholler
  • INDUCIBLE REGULATORY T-CELL GENERATION FOR HEMATOPOIETIC TRANSPLANTS
    Publication number: 20190022199
    Abstract: The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.
    Type: Application
    Filed: June 20, 2018
    Publication date: January 24, 2019
    Inventors: James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen
  • Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
    Patent number: 10174095
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: January 8, 2019
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Eugene Choi, Hilmar Erhard Ebersbach, David Glass, Heather Huet, Carl H. June, Joan Mannick, Michael C. Milone, Leon Murphy, Gabriela Plesa, Celeste Richardson, Marco Ruella, Reshma Singh, Yongqiang Wang, Qilong Wu
  • ICOS Critically Regulates the Expansion and Function of Inflammatory Human Th17 Cells
    Publication number: 20180371414
    Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
    Type: Application
    Filed: May 22, 2018
    Publication date: December 27, 2018
    Inventors: James L. Riley, Chrystal Paulos, Carl H. June, Bruce L. Levine
  • Compositions and Methods for Generating a Persisting Population of T Cells Useful for the Treatment of Cancer
    Publication number: 20180371068
    Abstract: The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.
    Type: Application
    Filed: June 21, 2018
    Publication date: December 27, 2018
    Inventors: Matthew J. Frigault, Yangbing Zhao, John Scholler, Carl H. June
  • METHODS FOR B CELL PRECONDITIONING IN CAR THERAPY
    Publication number: 20180334490
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to the methods of preconditioning a subject, e.g., by depleting B cells in combination with the use of a cell comprising a chimeric antigen receptor (CAR) that targets a tumor antigen as described herein. The methods for preconditioning the subject described herein include using a cell comprising a CAR that targets a B cell antigen as described herein.
    Type: Application
    Filed: December 2, 2015
    Publication date: November 22, 2018
    Inventors: Jennifer Brogdon, Gregory Beatty, David Glass, Carl H. June, Joan Mannick, Michael Milone, Leon Murphy, Gabriela Plesa, Huijuan Song, Qilong Wu
  • Use of a trans-signaling approach in chimeric antigen receptors
    Patent number: 10117896
    Abstract: The present invention provides compositions and methods for inducing a CAR mediated trans-signal in a T cell. The trans-signaling CAR T cells comprise a first CAR having a first signaling module and a second CAR having a distinct second signaling module. The present invention also provides cells comprising a plurality of types of CARs, wherein the plurality of types of CARs participate in trans-signaling to induce T cell activation.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: November 6, 2018
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Daniel J. Powell, Jr., Carl H. June